Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 18, 2017; 88 (16 Supplement) April 25, 2017

Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001)

Jacqueline French, Elizabeth Thiele, Maria Mazurkiewicz-Beldzinska, Selim Benbadis, Eric Marsh, Charuta Joshi, Claire Roberts, Adam Taylor, Ken Sommerville
First published April 17, 2017,
Jacqueline French
1New York Langone Medical Center New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Thiele
2Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Mazurkiewicz-Beldzinska
3Gdańsk Medical University Gda?sk Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Selim Benbadis
4University of South Florida Tampa FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Marsh
5Children’s Hospital of Philidelphia Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charuta Joshi
6Children’s Hospital Colorado Aurora CO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Roberts
7GW Pharmaceuticals Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Taylor
7GW Pharmaceuticals Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Sommerville
7GW Pharmaceuticals Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001)
Jacqueline French, Elizabeth Thiele, Maria Mazurkiewicz-Beldzinska, Selim Benbadis, Eric Marsh, Charuta Joshi, Claire Roberts, Adam Taylor, Ken Sommerville
Neurology Apr 2017, 88 (16 Supplement) S21.001;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate efficacy of CBD added to antiepileptic drug (AED) therapy for the treatment of seizures associated with LGS.

Background: Multiple data streams suggest that CBD may be an effective antiepileptic treatment; however, class 1 evidence supporting its use is lacking. Here we present the first controlled trial of CBD in LGS.

Design/Methods: Eligible patients were 2–55 years old and had a clinical diagnosis of LGS, ≥2 drop seizures each week during baseline, and documented failures on ≥1 AED. Patients were randomized (1:1) to receive 20 mg/kg/day CBD (oral solution) or matched placebo, for 14 weeks (2-week titration; 12-week dose maintenance). The primary efficacy endpoint was percentage change from baseline in drop seizure frequency (tonic, atonic, and tonic-clonic) over the entire 14-week treatment period for patients on CBD vs placebo.

Results: 171 patients were randomized (86 CBD; 85 placebo); 14 CBD and 1 placebo patient withdrew early. Demographic and baseline characteristics were evenly distributed between groups; mean age was 15 years (34% of patients ≥18 years) and median drop seizure frequency was 74/month. Patients had previously taken a median of 6 AEDs, and were taking a median of 3 concomitant AEDs throughout the trial. CBD resulted in a significantly greater median percent reduction in monthly drop seizure frequency, versus placebo (44% vs. 22%; p=0.0135). The treatment difference was established during the first 4 weeks of the maintenance period. 86% of CBD and 69% of placebo patients had adverse events (AEs); the most common were diarrhea, somnolence, pyrexia, decreased appetite, and vomiting. Treatment-related serious AEs were reported in 9 CBD patients and 1 placebo patient. There was 1 death (CBD), considered unrelated to treatment.

Conclusions: Results from this trial suggest that CBD add-on therapy for the treatment of drop seizures associated with LGS may be efficacious and generally well-tolerated. (NCT02224690)

Study Supported by:

GW Research, Ltd

Disclosure: Dr. French has received personal compensation for activities with Acorda, Adamas, Alexza, Anavex, Biogen, BioPharm Solutions, Cerecor, Concert Pharmaceuticals, Convance, Eisai, Georgia Regents University, GSK, GW Pharma, Marinus, MonosolRx, Monteris, Nestle-Health Science, Neurelis, Novartis, Ovid Therapeutics Inc., Pfizer, Pfizer-Neusentis, Pronutria, Roivant, Sage, SK Life Sciences, Sunovion, Supernus, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix, Zynerba as a consultant. Dr. Thiele has received personal compensation for activities with GW Pharma, Zogenix, Eisai Pharmaceuticals, Dravet, Lennox Gastaut and TSC as a consultant or PI. Dr. Thiele has received research support from GW Pharma and Zogenix. Dr. Mazurkiewicz-Beldzin has received personal compensation for activities with UCB and TEVA Pharmaceuticals as an advisory board member. Dr. Benbadis has received personal compensation for activities with Cyberonics, Eisai, Inc., Lundbeck, Sunovion and UCB Pharma. Dr. Benbadis has received personal compensation in an editorial capacity for eMedicine, WebMD, Medscape, and Up-To-Date. Dr. Marsh has received personal compensation for activities with GLC Consultants and SBSE. Dr. Marsh has received research support from GW Pharma and Neuren Pharmacuticals. Dr. Joshi has nothing to disclose. Dr. Roberts has received personal compensation for activities with GW Pharma as an employee. Dr. Taylor has nothing to disclose. Dr. Sommerville has received personal compensation for activities with King Pharmaceuticals as an employee. Dr. Sommerville holds stock and/or stock options in GW, Abbott, Abbvie, Johnson and Johnson, Mylan, and Merck.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise